Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.

Cited by (454)

Items 101–200 of 454

1. Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
   Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Hitoshi Arioka, Hirotoshi Iihara, Mitsuhiro Sugawara, Hajime Morita, Ayako Mochizuki, Shuichi Nawata, Keisuke Mishima et al. · 2023 · British Journal of Cancer
2. Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice
   Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Stefania Zambelli, Patrizia Zucchinelli, Marta Piras, Carlo Bosi, Marco Mariani et al. · 2024 · Frontiers in Oncology
3. The prevention and treatment of nausea and vomiting during tumor therapy
   Franziska Jahn, Bernhard Josef Wormann, Juliane Brandt, Annette Freidank, Petra Ch. Feyer, Karin Jordan · 2022 · Deutsches Ärzteblatt international
4. Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
   Yi Cheng, Zehua Wu, Lishuo Shi, Cailu Shen, Jianwei Zhang, Huabin Hu, Weiwei Li, Yue Cai, Xiaoyu Xie, Jiayu Ling et al. · 2022 · EClinicalMedicine
5. Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India
   Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anant Ramaswamy, Sudeep Gupta, Arvind Sahu, Vipul Doshi, Tarachand Gupta, Sushmita Rath, Shripad D. Banavali et al. · 2017 · Journal of Oncology Practice
6. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan
   Alaa A. Osman, Moawia Mohammed Ali Elhassan, Blala H.A. AbdElrahim, Fatima H.A. Ahmed, Jihad B.H. Yousif, Malak A.M. Ahmed, Romisa H.A. Abdelhafeez, Umsalama M.Y. Ahmed · 2018 · Journal of Global Oncology
7. Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial
   Chizuru Sakai, Mototsugu Shimokawa, Hirotoshi Iihara, Yukiyoshi Fujita, Shinnosuke Ikemura, Chiemi Hirose, Mie Kotake, Norihiko Funaguchi, Takenobu Gomyo, Hisao Imai et al. · 2021 · The Oncologist
8. Olanzapine for Chemotherapy-Induced Nausea and Vomiting
   Rudolph M. Navari, Charles L Loprinzi · 2016 · New England Journal of Medicine
9. Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin
   Yuanyuan Zhao, Bing Tian Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li et al. · 2022 · 癌症：英文版
10. Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study
    Hirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, Yoshimi Niwa, Yutaka Mizuno, Yoshihiro Kawaguchi, Mika Kitahora, Akari Murakami, Masaaki Kawai, Kazushige Ishida et al. · 2023 · Journal of Cancer
11. Chemotherapy-Induced Nausea and Vomiting Mitigation With Music Interventions
    Jason Micheal Kiernan, Jody Conradi Stark, April Hazard Vallerand · 2017 · Oncology nursing forum
12. 5HT3RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer
    Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Junichi Nishimura, Hirotoshi Iihara, Takafumi Nakano, Takashi Egawa · 2020 · Cancer Science
13. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial
    Jørn Herrstedt, Yvonne Summers, Karin Jordan, Joachim von Pawel, A. H. Jakobsen, Marianne Ewertz, Stephen Y.T. Chan, Jay Naik, Meinolf Karthaus, Sidharth Dubey et al. · 2018 · Supportive Care in Cancer
14. Chronic Atypical Antipsychotic Use Is Associated With Reduced Need for Postoperative Nausea and Vomiting Rescue in the Postanesthesia Care Unit: A Propensity-Matched Retrospective Observational Study
    Craig S. Jabaley, Dennis Gray, Gaurav Budhrani, Grant C. Lynde, Panagiotis Adamopoulos, George S. Easton, Vikas N. O’Reilly-Shah · 2019 · Anesthesia & Analgesia
15. Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy
    Daiki Tsuji, Megumi Matsumoto, Yohei Kawasaki, Yong-I. L. Kim, Keisuke Yamamoto, Hidenori Nakamichi, Yuri Sahara, Ryo Makuta, Mari Yokoi, Takehiro Miyagi et al. · 2020 · Cancer Chemotherapy and Pharmacology
16. Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
    Sayako Yuda, Shigeo Fuji, Bipin N. Savani, Katie S. Gatwood · 2022 · Clinical Hematology International
17. Anti-Emetics in Children Receiving Chemotherapy for Solid Tumors and Leukemia: Pharmacology and Optimization of Therapy for Nausea and Vomiting
    Shuvadeep Ganguly, Archana Sasi, Santhosh Kumar Kodagalli Nagaraju, Sameer Bakhshi · 2024 · Pharmaceuticals
18. Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug
    Xiaoling Zhang, Jie-Er Ying · 2022 · Current Oncology
19. Benefits and risks of off-label olanzapine use for symptom management in cancer patients—a case report
    Rony Dev, Edgardo S. Fortuno, Jaya Amaram‐Davila, Ali Haider, Eduardo D Bruera · 2023 · Annals of Palliative Medicine
20. Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study
    Xuan Wu, Jingxun Wu, Gangling Tong, Boran Cheng, Minhua Chen, Shaokang Yu, Lirui He, Zhu Li, Shubin Wang · 2020 · Cancer Management and Research
21. Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
    Mitsue Saito, Hirotoshi Iihara, Mototsugu Shimokawa, Ryoko Udagawa, Michiko Tsuneizumi, Manabu Futamura, Yuko Ishikawa, Hideaki Ogata, Hiroko Bando, Hiroaki Shima et al. · 2025 · The Lancet Oncology
22. An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department*
    Lauren R. Klein, Jon B. Cole, Brian E. Driver, James R. Miner, JoAn R. Laes, Erik T. Fagerstrom, Marc L. Martel · 2019 · Clinical Toxicology
23. Low-Dose Olanzapine, Sedation and Chemotherapy-Induced Nausea and Vomiting: A Prospective Randomized Controlled Study
    Sandip Mukhopadhyay, Premnath Dutta, Sanatan Banerjee, Biswamit Bhattacharya, Supreeti Biswas, Rudolph M. Navari · 2021 · Future Oncology
24. Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
    Senri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, Hitoshi Kawazoe, Kazuki Tanaka, Yukiyoshi Fujita, Masakazu Abé, Hisao Imai, Masato Karayama, Yoh Hayasaki et al. · 2021 · BMC Cancer
25. Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
    Amber Bradley Clemmons, Arpita P. Gandhi, Andrea Clarke, Sarah Jimenez, Thuy T. T. Le, Germame Hailegiorgis Ajebo · 2021 · Journal of the Advanced Practitioner in Oncology
26. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study
    Jiali Gao, Jun Zhao, Caihong Jiang, Feng Chen, Lanzhen Zhao, Ying Jiang, Hui Li, Wenjuan Wang, Yungaowa Wu, Yilan Jin et al. · 2022 · Supportive Care in Cancer
27. Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist
    Sitthi Sukauichai, Chaninun Ketkaew, Naparat Othaganont, Pichayapa Pichaya, Pimonwan Promsuwan · 2022 · Asian Pacific Journal of Cancer Prevention
28. Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy
    Lee Steven Schwartzberg, Trent P. McLaughlin, Robert B. Geller, Nashat Y. Gabrail, Stanley M. Marks · 2018 · Journal of Comparative Effectiveness Research
29. Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
    Hitoshi Kawazoe, Ryuji Uozumi, Akari Murakami, Michiko Yamashita, Kana Kobayashi-Taguchi, Erina Kusakabe, Haruna Yamasawa, Yoshihiro Yakushijin, Tomonori Nakamura, Yoshiaki Kamei · 2018 · Scientific Reports
30. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients
    Ronald Chow, Leonard Chiu, Jørn Herrstedt, Matti Aapro, Michael I. Lock, Carlo DeAngelis, Rudolph M. Navari · 2021 · Supportive Care in Cancer
31. A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple‐Day Cisplatin Chemotherapy‐Induced Nausea and Vomiting
    Guang Liu, Yilan Jin, Ying Jiang, Juan Zhao, Caihong Jiang, Zewei Zhang, Lanzhen Zhao, Hui Li, Feng Chen, Jing Wang et al. · 2022 · International Journal of Clinical Practice
32. Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective
    Masakazu Abé, Hirotoshi Iihara, Kenjiro Aogi · 2023 · Advances in Therapy
33. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
    Naoki Inui, Takahito Suzuki, Kazuki Tanaka, Masato Karayama, Yusuke Inoue, Kazutaka Mori, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi et al. · 2024 · Journal of Clinical Oncology
34. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting
    Adile Orhan, Carolyn Nguyen, Alexandre Chan, Jørn Herrstedt · 2024 · Expert Opinion on Drug Metabolism & Toxicology
35. Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
    East Japan Chesters Group, Toshimichi Miya, Kunihiko Kobayashi, Mitsunori Hino, Masahiro Ando, Susumu Takeuchi, Masahiro Seike, Kaoru Kubota, Akihiko Gemma · 2016 · SpringerPlus
36. Diabetes and the Stomach
    Allen A. Lee, William Lee Hasler · 2017 · Current Treatment Options in Gastroenterology
37. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
    Bernardo Leon Rapoport, Matti Aapro, Martin Robert Chasen, Karin Jordan, Rudolph M. Navari, Ian D. Schnadig, Lee Steven Schwartzberg · 2017 · Drug Design Development and Therapy
38. Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Anthracycline-cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer.
    Alimohammad Maleki, Mojtaba Ghadyani, Jamshid Salamzadeh, Sina Salari, Seyedshahab Banihashem, Maria Tavakoli Ardakani · 2020 · PubMed Central
39. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
    Karun Neupane, Ahsan Wahab, Adeel Masood, Tehniat Faraz Ahmed, Saman Bahram, Hamid Ehsan, Abdul Hannan, Faiz Anwer · 2021 · Journal of Blood Medicine
40. Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy
    Nikita Mehra, Prasanth Ganesan, Trivadi Sundaram Ganesan, Surendran Veeraiah, Abirami Boopathy, Venkatraman Srinivasan Radhakrishnan, Manikandan Dhanushkodi, Rajaraman Swaminathan, Sevaluxmy Ganesharajah, Tenali Gnana Sagar · 2017 · Medical Oncology
41. Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
    Rudolph M. Navari, Bernardo Leon Rapoport, Dan Powers, Sujata Arora, Rebecca Anne Clark-Snow · 2018 · Cancer Medicine
42. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
    Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Kōichi Goto, Reiko Matsui, Nobuhiko Seki, Toshikazu Shimada et al. · 2018 · Journal of Pharmaceutical Health Care and Sciences
43. Preventing Chemotherapy-Induced Nausea and Vomiting with Netupitant/Palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective
    Matti Aapro, Li Zhang, Sriram Yennurajalingam, Thomas William LeBlanc, Lee Steven Schwartzberg · 2019 · Future Oncology
44. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
    R. de las Peñas, Ana Blasco, Javier de Castro, Yolanda Escobar, Rosario García‐Campelo, Alfonso Gúrpide, Rafael López‐López, Margarita Majem, Cesar Augusto Rodriguez, Juan Antonio Virizuela · 2016 · Clinical & Translational Oncology
45. Creation and evaluation of a cancer chemotherapy order review guide for use at a community hospital
    Alexandra P. Punke, JA Waddell · 2017 · Journal of Oncology Pharmacy Practice
46. Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy
    Masakazu Abé, Takuhiro Yamaguchi, Yukiyoshi Fujita, Tomoyasu Nishimura, Koichi Kitagawa, Naoki Inui, Katsuya Hirano, Yukio Sakata, Hirotoshi Iihara, Yuichi Shibuya et al. · 2023 · JAMA Network Open
47. Should Olanzapine be Advocated Over Conventional Anti-Emetics for the Prevention of Chemotherapy-Induced Nausea and Vomiting? An Updated Meta-Analysis of Randomized Control Trials
    Eshak I. Bahbah, Ahmed Ramadan Abdalla, Khalid Abdelshafy, Ahmed Diaa Almohandes, Amr Menshawy, Mohamed Abd Elalem Aziz, Mahmoud Ahmed Ebada, Awad Mohammed Hegab, Ahmed Negida · 2019 · Current Enzyme Inhibition
48. Investigation of Clozapine and Olanzapine Reactive Metabolite Formation and Protein Binding by Liquid Chromatography-Tandem Mass Spectrometry
    Timon Geib, Madhuranayaki Thulasingam, Jesper Z. Haeggström, Lekha Sleno · 2020 · Chemical Research in Toxicology
49. The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis
    Dongyang Wang, Yi Chen, You Zhang, Yingqiang Shen · 2021 · Frontiers in Oncology
50. Optimal Prophylaxis of Chemotherapy-Induced Nausea and Vomiting for Moderately Emetogenic Chemotherapy: A Meta-Analysis
    Yaxiong Zhang, Xue Hou, Rong Zhang, Gang Chen, Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Shiyang Kang et al. · 2018 · Future Oncology
51. Medicinal cannabinoids in palliative care
    Meera Ruth Agar · 2018 · British Journal of Clinical Pharmacology
52. Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach
    Florian Scotté · 2017 · Annals of Oncology
53. Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT
    Huaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang, Jun Yao, Shuang Leng, Xiu-Min Li, Lin Li, J Chen, Songnan Zhang, Xia Qin et al. · 2024 · Journal of Clinical Oncology
54. Nausées-vomissements induits par les traitements anti-cancéreux (NVITAC) : quelle prise en charge en 2018 ? Mise à jour du référentiel AFSOS
    Nicolas Jovenin, Audrey Eche-Gass, Stéphane Chèze, Vincent Launay‐Vacher, Didier Mayeur, Jean‐Baptiste Rey, Florence Joly, I. Krakowski, Florian Scotté · 2019 · Bulletin du Cancer
55. Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study
    Luigi Celio, Gabriella Saibene, Stefano Lepori, Fabrizio Festinese, Monica Niger, Francesco Raspagliesi, Domenica Lorusso · 2019 · Tumori Journal
56. Evaluating Chemotherapy-induced Nausea and Vomiting and Food Intake in Patients With Gynecologic Cancer
    Hiroaki Komatsu, Tetsuro Oishi, Shinya Sato, Daiken Osaku, Mayumi Sawada, Akiko Kudoh, Michiko Nonaka, Seiya Sato, Muneaki Shimada, Hiroaki Itamochi et al. · 2019 · Anticancer Research
57. Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult
    Sarah Bonar, Harold L. Schneider, Katherine Cook, Renato Verayo Samala, Michelle Fontilla Poole · 2023 · Journal of Pain and Symptom Management
58. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score–matched analysis
    Toshinobu Hayashi, Mototsugu Shimokawa, Fumitaka Mizuki, Koichi Matsuo, Kei Kawada, Takafumi Nakano, Takashi Egawa · 2021 · Supportive Care in Cancer
59. Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice
    Abigail Boyd, Ileana V. Aragon, Justin Rich, Will McDonough, Marianna Oditt, Daniel W. Irelan, Edward Fiedler, Lina Abou Saleh, Wito Richter · 2021 · Biology
60. Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study
    Jørn Herrstedt, Yvonne Summers, Gedske Daugaard, Thomas B. Christensen, Karin Holmskov, Paul D. Taylor, Gabriel M. Fox, Alex Molassiotis · 2017 · Supportive Care in Cancer
61. Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine
    Winnie Yeo, Vicky T.C. Chan, Leung Li, Thomas K.H. Lau, Kwai Tung Lai, Elizabeth Pang, Maggie S.H. Cheung, Frankie K. F. Mo · 2020 · Data in Brief
62. Research trends on chemotherapy induced nausea and vomiting: a bibliometric analysis
    Chunhui Ning, Yunzi Yan, Yansong Wang, Rui Li, Wenjie Liu, Linjie Qiu, Lingyun Sun, Yufei Yang · 2024 · Frontiers in Pharmacology
63. Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy
    Hironobu Hashimoto, Masakazu Abé, Takako Yanai, Takuhiro Yamaguchi, Sadamoto Zenda, Yosuke Uchitomi, Haruhiko Fukuda, Mikio Mori, Satoru Iwasa, Noboru Yamamoto et al. · 2018 · Japanese Journal of Clinical Oncology
64. P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats
    Yuan Xu, Jian Lu, Bingyi Yao, Yuanjin Zhang, Shengbo Huang, Jie Liu, Yanfang Zhang, Yuanqing Guo, Xin Wang · 2021 · Toxicology and Applied Pharmacology
65. Male and female rats exhibit comparable gaping behavior but activate brain regions differently during expression of conditioned nausea
    Alyssa Bernanke, Samantha Sette, Nathaniel Hernandez, Sara Zimmerman, Justine Murphy, Reynold Francis, Zackery W. Reavis, Cynthia M. Kuhn · 2022 · Behavioural Pharmacology
66. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase
    Naoki Inui, Yukihiro Toi, Yasuto Yoneshima, Masahiro Morise, Akito Hata, Kaoru Kubota, Toshiaki Saeki, Tomohide Tamura · 2023 · Advances in Therapy
67. Bibliometric and visual analysis of chemotherapy-induced nausea and vomiting (2004-2023)
    Shao-Chuang Tian, Jing Yang, Xin Li, Rong-Xia Huang, Jian Chen · 2024 · Frontiers in Oncology
68. Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
    Bernardo Leon Rapoport · 2017 · Cancer Management and Research
69. Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting – A systematic review and meta-analysis
    Ajay Raghunath, Sahan D. Chandrasekara, Shane N. Anthony, Ben Markman · 2020 · Critical Reviews in Oncology/Hematology
70. Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients
    Naoki Fukuda, Mayu Yunokawa, Yu Fujiwara, Xiaofei Wang, Akihiro Ohmoto, Naomi Hayashi, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono et al. · 2020 · Cancer Reports
71. Référentiels inter régionaux en Soins Oncologiques de Support
    2017 · ONCOLOGIE
72. A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients
    Junichi Nishimura, Akiko Hasegawa, Toshihiro Kudo, Tomoyuki Otsuka, Masayoshi Yasui, Chu Matsuda, Naotsugu Haraguchi, Hajime Ushigome, Nozomu Nakai, Tomoki Abe et al. · 2021 · Scientific Reports
73. Getting it right the first time: recent progress in optimizing antiemetic usage
    Lee Steven Schwartzberg · 2018 · Supportive Care in Cancer
74. Cisplatin-Based Therapy and CINV: Optimal Antiemetics During Germ Cell Testicular Cancer Treatment
    Meghan Mastrangelo · 2018 · Clinical journal of oncology nursing
75. Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
    Vincenzo Apolito, Luisa Giaccone, Simone Ferrero, Alessandra Larocca, Federica Cavallo, Marta Coscia, Eloise Beggiato, Sara Butera, Federica Martella, Cristina Dainese et al. · 2020 · Annals of Hematology
76. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation
    Joseph S. Bubalo, Jennifer L. Radke, Kenneth G Bensch, Andy I. Chen, Shikha Misra, Richard Thomas Maziarz · 2023 · Journal of Oncology Pharmacy Practice
77. Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy
    Naoki Inui · 2017 · Medical Oncology
78. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
    Ian D. Schnadig, Richy Agajanian, Christopher S. R. Dakhil, Nashat Y. Gabrail, Jeffrey L. Vacirca, Charles Taylor, Sharon T. Wilks, Eduardo Braun, Michael C. Mosier, Robert B. Geller et al. · 2017 · Cancer Management and Research
79. A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches
    Paolo Bossi, Mario Airoldi, Maria Antonietta Aloe Spiriti, Andrea Antonuzzo, Giorgio Bonciarelli, Alessia Campagna, Alessandra Cassano, Roberto Murialdo, Daniela Musio, Giovanni Silvano · 2020 · Expert Opinion on Drug Safety
80. Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide
    Marii Suehiro, Yasuyuki Kojima, Masaki Takahashi, Yuka Ito, Takayuki Keira, Kiwako Ikegawa, Hiroko Minatogawa, Koichiro Tsugawa, Tsuneaki Tanaka · 2021 · Cancer Management and Research
81. Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial
    Abdul W. Moothedath, Jagdish P. Meena, Aditya K. Gupta, Thirumurthy Velpandian, Ravindra M. Pandey, Rachna Seth · 2022 · Journal of Pediatric Hematology/Oncology
82. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy
    Florian Slimano, Florence Netzer, Isabelle Borget, François Lemare, Benjamin Besse · 2018 · International Journal of Clinical Pharmacy
83. The clinical effect of an electric massage chair on chemotherapy-induced nausea and vomiting in cancer patients: randomized phase II cross-over trial
    Ju Won Kim, Ah Reum Lim, Ji Yoon Lee, Juneyoung Lee, Soo Hyun Lee, Yoon Ji Choi, Yeul Hong Kim, Kyong Hwa Park · 2024 · BMC Complementary Medicine and Therapies
84. Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology
    Michiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, Masakazu Abé, Junichi Nishimura, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura et al. · 2024 · International Journal of Clinical Oncology
85. Effect of non-pharmacological interventions on chemotherapy induced delayed nausea and vomiting for tumors: A systematic review and Bayesian network meta-analysis
    Yongni Wang, Fang Wang, Feifei Hu, Fang Long · 2025 · Complementary Therapies in Medicine
86. Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy
    Seiko Bun, Kan Yonemori, Toru Akagi, Emi Noguchi, Tatsunori Shimoi, Akihiko Shimomura, Mayu Yunokawa, Chikako Shimizu, Yasuhiro Fujiwara, Yoshinori Makino et al. · 2017 · Investigational New Drugs
87. Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta‐analysis of 143 randomized controlled trials
    Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang, Kaixiong Tao · 2017 · International Journal of Cancer
88. Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial
    Hao Wei, Yu Sun, Lingling Xie, Yuming Jia, Jun He, Xiaofei Deng, Wei Huang, Yang Hu, Jiang Zhu · 2023 · Journal of Integrative and Complementary Medicine
89. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
    Noha Rashad, Omar Mohammed Abdel-Rahman · 2017 · Drug Design Development and Therapy
90. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting
    Lee Steven Schwartzberg, Stanley M. Marks, Nashat Y. Gabrail, Robert B. Geller, Jonathan Karl Kish · 2019 · Journal of Comparative Effectiveness Research
91. Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy
    HIRONORI FUJII, Hirotoshi Iihara, Noriko Kajikawa, Ryo Kobayashi, Akio Suzuki, Yoshihiro Tanaka, Kazuya Yamaguchi, Kazuhiro Yoshida, Yoshinori Itoh · 2017 · Anticancer Research
92. Symptom relief and palliative care in gynecologic oncology
    Mohana Roy, Kavitha J. Ramchandran · 2019 · Current Opinion in Obstetrics & Gynecology
93. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study
    Peipei Ye, Renzhi Pei, Tiantian Wang, Junjie Cao, Pisheng Zhang, Dong Chen, Xuhui Liu, Xiaohong Du, Shuangyue Li, Shanhao Tang et al. · 2022 · Annals of Hematology
94. Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence
    Diana J. Lu, Michael Luu, Anthony Tuan Nguyen, Kevin S. Scher, Jon Mallen‐St. Clair, Alain C. Mita, Stephen Lawrence Shiao, Allen S. Ho, Zachary Stephan Zumsteg · 2019 · Oral Oncology
95. A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”
    Meenu Vijayan, Sherin John Joseph, Emmanuel James, Debnarayan Dutta · 2021 · Journal of Oncology Pharmacy Practice
96. Acupuncture Point Selection Patterns for Chemotherapy-Induced Nausea and Vomiting: A Data Mining Analysis
    Zi Ke, Hongruyu Chen, Yong Zhao, Jixian Ke, Youqiong Xie, Runxin Zeng, Yini Hua, Zhihao Xiong, Xuanxuan Wang · 2024 · Complementary Medicine Research
97. Best Practices in Caring for Seriously Ill Patients
    Rachelle Bernacki, Vyjeyanthi S. Periyakoil · 2024 · Annals of Internal Medicine
98. The Pharmacological and Clinical Roles of Antiemetics: A Narrative Review
    Alan D. Kaye, Donovan Turpin, Shivam Shah, Brennan M Abbott, Alex V Hollander, Caroline R Burroughs, Sarah H. Myers, Shahab Ahmadzadeh, Jibin Sam Mathew, Adam Marc Kaye et al. · 2025 · Cureus
99. Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study
    Takashi Yokokawa, Kenichi Suzuki, Daiki Tsuji, Mari Hosonaga, Kazuo Kobayashi, Kazuyoshi Kawakami, Hitoshi Kawazoe, Tomonori Nakamura, Wataru Suzuki, Takahito Sugisaki et al. · 2023 · Cancer Medicine
100. Olanzapine for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a randomized controlled trial
     Nanjin Chen, Shuman Ji, Junfei Liu, Liping Wang, Fenglin Chen, Yanwu Zhu, Jiao Li, Minjuan Chen, Lingyang Chen, Mingcang Wang et al. · 2024 · Therapeutic Advances in Drug Safety